Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model.
暂无分享,去创建一个
Stefan Vogt | Xiaobing Fan | Gregory S Karczmar | Gayle E Woloschak | Tatjana Paunesku | Gillian M Newstead | Thomas Krausz | Sanaz A Jansen | T. Paunesku | G. Newstead | S. Jansen | G. Karczmar | G. Woloschak | S. Conzen | Xiaobing Fan | S. Vogt | T. Krausz | Suzanne D Conzen
[1] R. Schmidt,et al. Pure ductal carcinoma in situ: kinetic and morphologic MR characteristics compared with mammographic appearance and nuclear grade. , 2007, Radiology.
[2] W. Kaiser,et al. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. , 2003, The British journal of radiology.
[3] D. D. Billheimer,et al. Repeatability of a reference region model for analysis of murine DCE‐MRI data at 7T , 2006, Journal of magnetic resonance imaging : JMRI.
[4] S. Lutsenko,et al. Quantitative imaging of metals in tissues , 2009, BioMetals.
[5] R. Warren,et al. Characterization of pure high-grade DCIS on magnetic resonance imaging using the evolving breast MR lexicon terminology: can it be differentiated from pure invasive disease? , 2005, Magnetic resonance imaging.
[6] G. Newstead,et al. MR imaging of the breast. , 1995, Radiology.
[7] G Lutterbey,et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. , 1997, Radiology.
[8] Robert J. Erhardt,et al. Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? , 2005, Neurological research.
[9] Simone Schrading,et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study , 2007, The Lancet.
[10] Cheryl Jorcyk,et al. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma , 2000, Oncogene.
[11] S. Harms. The Use of Breast Magnetic Resonance Imaging in Ductal Carcinoma in Situ , 2005, The breast journal.
[12] Claudia Weidensteiner,et al. Quantitative dynamic contrast‐enhanced MRI in tumor‐bearing rats and mice with inversion recovery TrueFISP and two contrast agents at 4.7 T , 2006, Journal of magnetic resonance imaging : JMRI.
[13] Elizabeth A Morris,et al. Determination of the Presence and Extent of Pure Ductal Carcinoma in Situ by Mammography and Magnetic Resonance Imaging , 2005, The breast journal.
[14] Daniel F Chen,et al. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Michael Brady,et al. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast , 2005, Medical Image Anal..
[16] J. Green,et al. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[17] Xiaobing Fan,et al. Comparison and evaluation of mouse cardiac MRI acquired with open birdcage, single loop surface and volume birdcage coils , 2006, Physics in medicine and biology.
[18] G. Newstead,et al. Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation , 2008, Physics in medicine and biology.
[19] Edna Schechtman,et al. Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions , 2005, Cancer.
[20] M. Mehta,et al. Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. , 2001, Cancer research.
[21] M. Yaffe,et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .
[22] T. Frenzel,et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.
[23] U. Fischer,et al. MR imaging of mammographically detected clustered microcalcifications: is there any value? , 1998, Radiology.
[24] B. Lai,et al. Gadolinium-conjugated TiO2-DNA oligonucleotide nanoconjugates show prolonged intracellular retention period and T1-weighted contrast enhancement in magnetic resonance images. , 2008, Nanomedicine : nanotechnology, biology, and medicine.
[25] O Lucidarme,et al. Clustered breast microcalcifications: evaluation by dynamic contrast-enhanced subtraction MRI. , 1996, Journal of computer assisted tomography.
[26] Stefan Vogt,et al. DNA-TiO2 nanoconjugates labeled with magnetic resonance contrast agents. , 2007, Journal of the American Chemical Society.
[27] M. Schnall,et al. MR imaging of ductal carcinoma in situ. , 1997, Radiology.
[28] Wei Huang,et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo , 2008, Proceedings of the National Academy of Sciences.
[29] Stefan Vogt,et al. MAPS : A set of software tools for analysis and visualization of 3D X-ray fluorescence data sets , 2003 .
[30] G S Karczmar,et al. A new method for imaging perfusion and contrast extraction fraction: Input functions derived from reference tissues , 1998, Journal of magnetic resonance imaging : JMRI.